MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Ultragenyx Pharmaceutical Inc

Fermé

SecteurSoins de santé

35.34 4.59

Résumé

Variation du prix de l'action

24h

Actuel

Min

33.5

Max

35.38

Chiffres clés

By Trading Economics

Revenu

131K

-133M

Ventes

25M

165M

BPA

-1.39

Marge bénéficiaire

-80.9

Employés

1,294

EBITDA

-59K

-109M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+177.96% upside

Dividendes

By Dow Jones

Prochains Résultats

1 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-44M

3.5B

Ouverture précédente

30.75

Clôture précédente

35.34

Sentiment de l'Actualité

By Acuity

45%

55%

165 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Ultragenyx Pharmaceutical Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 avr. 2025, 23:55 UTC

Actions en Tendance

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 avr. 2025, 22:50 UTC

Principaux Mouvements du Marché

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 avr. 2025, 21:08 UTC

Résultats

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 avr. 2025, 21:00 UTC

Résultats

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 avr. 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 avr. 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 avr. 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 avr. 2025, 23:44 UTC

Actualités

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 avr. 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 avr. 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 avr. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 avr. 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 avr. 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 avr. 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 avr. 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 avr. 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 avr. 2025, 22:43 UTC

Actualités
Acquisitions, Fusions, Rachats

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 avr. 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 avr. 2025, 21:48 UTC

Actualités

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 avr. 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 avr. 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 avr. 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 avr. 2025, 21:04 UTC

Actualités

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 avr. 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 avr. 2025, 20:53 UTC

Résultats

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 avr. 2025, 20:52 UTC

Résultats

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparaison

Variation de prix

Ultragenyx Pharmaceutical Inc prévision

Objectif de Prix

By TipRanks

177.96% hausse

Prévisions sur 12 Mois

Moyen 94.06 USD  177.96%

Haut 140 USD

Bas 47 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

17 ratings

16

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 38.86Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

165 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.